Fiocruz (Fundação Oswaldo Cruz) announced on Friday (February 12, 2021) that it was negotiating the import of 2 million doses of the vaccine manufactured by the AstraZanteca laboratory, in partnership with Instituto Serum from India. The objective is to guarantee the supply of antibodies, while the Brazilian unit produces new supplements in the national arena.
Earlier, Anvisa (National Health Monitoring Agency) approved the import of new doses of vaccine. It will be up to the Ministry of Health to decide whether it will hold only 2 million doses that Turquoise intends to import or if there will be new orders.
Earlier this year, the agency had already authorized the import of another 2 million doses of the vaccine produced in India.